Annual Report 2021-2023
Tays Cancer Centre unites cancer treatment and research at the University Hospital across organizational boundaries with cancer research and education of the professionals of the field at the Tampere University
Tays Cancer Centre was established in 2016–2019 as a result of a quality audit performed by the Organisation of European Cancer Institutes (OECI). The OECI Cancer Centre certificate was granted to us on 20.9.2019. We can thank the decision-makers at the time for starting the audit process: Kari-Matti Hiltunen, Chief Medical Officer and Rauno Ihalainen, Director of the Hospital District from the Pirkanmaa Hospital District, Professor of Oncology Pirkko-Liisa Kellokumpu-Lehtinen from the University of Tampere and Dean of the Faculty of Medicine in the University of Tampere Tapio Visakorpi. A lot of good things have come out of this union, for example, patient pathways have become more fluent, cooperation and communication between professionals have increased, research has become more important than before, and the voices of patients and service users have been heard more strongly. We do this work here at the hospital and at the university, ultimately for those who are affected by cancer in some form. In 2024, we are preparing for a new audit. In this Annual Report 2021-2023, we tell you some key information about our work – we hope you find something interesting to read.
Annika Auranen
Chief Physician, Director
Tays Cancer Centre and Regional cancer center FICAN Mid
In Tays Cancer Centre, treatment relies on a unique cancer team model and a strong patient-oriented approach
The treatment of childhood cancers in Tampere is world-class
The patient jury has a significant impact on the development of Tays Cancer Centre’s services
Molecular profiling of tumors and investments in research promote tailored treatment of cancers
Cell-free tumour DNA examined from body fluids facilitates cancer detection and monitoring
Real World study based on actual patient data shows the effectiveness of treatment
Key Figures 2021–2023